Despite works that have shown an increase in PD-L1 expression via IL-6/JAK/STAT3 [66] or p-ERK1/2/p-c-Jun signaling but not through the p-AKT/p-S6 pathway [67], Biton et al. found that EGFR-mutated NSCLC cells were found to have a lower PD-L1 expression and weaker immunogenic TME [68]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.